Approach to febrile neutropenia in patients undergoing treatments for hematologic malignancies

Erica J. Stohs, Anum Abbas, Alison Freifeld

Research output: Contribution to journalReview articlepeer-review

Abstract

Febrile neutropenia (FN) is common among hematologic malignancy patients, including recipients of hematopoietic cell transplantation (HCT) and cellular therapies such as chimeric antigen receptor (CAR)-T-cell therapy. Prompt empiric antibiotic use has been the mainstay for decades but a “one-size-fits-all” approach is no longer broadly accepted, as treatment-related infectious risk are more understood. Growing antimicrobial resistance is an increasing clinical challenge. Evolving strategies on de-escalation of broad-spectrum antibiotics in FN without identified infection are areas of particular interest.

Original languageEnglish (US)
Article numbere14236
JournalTransplant Infectious Disease
Volume26
Issue number2
DOIs
StatePublished - Apr 2024

Keywords

  • antimicrobial stewardship
  • fever
  • hematologic malignancy
  • hematopoietic cell transplantation
  • neutropenia

ASJC Scopus subject areas

  • Transplantation
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Approach to febrile neutropenia in patients undergoing treatments for hematologic malignancies'. Together they form a unique fingerprint.

Cite this